Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$194k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
17.6% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
20
users have followed this narrative
New
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
1.1% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
17
users have liked this narrative
7
users have commented on this narrative
23
users have followed this narrative
9 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
4.7% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
18
users have liked this narrative
7
users have commented on this narrative
20
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
47.4% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Milestone Scientific
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Healthcare Cost Pressures Will Limit Adoption Yet Progress Will Emerge
Key Takeaways Premium pricing and cautious healthcare spending could slow adoption and restrict future revenue, especially as hospitals limit capital expenditures. Ongoing net losses and delayed diversification may require new financing, increasing dilution risk and putting pressure on future profit margins.
View narrative
US$1.25
FV
52.2% undervalued
intrinsic discount
25.71%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
ITM Power
AN
AnalystLowTarget
Consensus Narrative from 11 Analysts
Rising Financing And Geopolitical Risks Will Hamper Hydrogen Infrastructure
Key Takeaways Elevated financing barriers, policy uncertainty, and rising competition threaten ITM Power's project pipeline, future demand, and contract profitability. Ongoing cost control challenges and margin pressures from supply chains and under-absorbed costs may delay sustained profitability despite revenue growth.
View narrative
UK£0.36
FV
84.1% overvalued
intrinsic discount
53.58%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
New
narrative
NeuroPace
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
Rising Regulatory Pressures Will Undermine Neurotech And Spur Cautious Optimism
Key Takeaways Persistent pricing pressure, data privacy concerns, and a limited addressable market threaten revenue growth and sustainable operating margins. Industry shifts toward non-invasive solutions and substantial investment needs may undermine sales volume, profitability, and long-term cash flow.
View narrative
US$13.00
FV
33.4% undervalued
intrinsic discount
13.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
New
narrative
Nyxoah
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
FDA And Payer Challenges Will Constrain Rollout Yet Hint Potential
Key Takeaways Long-term growth relies on US adoption, yet clinician hesitancy, payers' pricing pressures, and larger competitors' innovation could hinder revenue and margin expansion. High initial investments and exposure to operational, supply chain, and regulatory risks may prolong operating losses and challenge Nyxoah's path to sustained profitability.
View narrative
€7.00
FV
22.3% undervalued
intrinsic discount
179.22%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Rackspace Technology
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Public Cloud Competition Will Erode Managed Revenues But Spark Recovery
Key Takeaways The rise of public cloud hyperscalers and automation threatens Rackspace's managed services demand and erodes long-term differentiation in a commoditized market. Growing enterprise use of native cloud tools and direct provider relationships may bypass Rackspace, creating ongoing pressure on revenue, margins, and earnings stability.
View narrative
US$1.40
FV
18.6% undervalued
intrinsic discount
1.90%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
ENNOSTAR
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Global Uncertainty Will Erode LED And Automotive Margins
Key Takeaways Weak demand and intensified competition threaten profitability and may cause long-term revenue declines amid rapid industry and technology changes. Trade barriers, currency volatility, and heavy investment needs elevate operational risks and strain future financial flexibility.
View narrative
NT$29.00
FV
31.4% overvalued
intrinsic discount
5.76%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Schrödinger
AN
AnalystLowTarget
Consensus Narrative from 10 Analysts
Margins And Revenue Challenges Will Slow Progress Yet Kindle Potential
Key Takeaways Reliance on large pharma clients and high R&D outlays limit revenue growth and keep earnings negative despite new product initiatives and expanding collaborations. Intensifying competition, slow adoption by new customers, and regulatory uncertainties challenge sustained pricing power and margin improvement.
View narrative
US$20.46
FV
5.4% undervalued
intrinsic discount
14.38%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Equinox Gold
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
Greenstone And Valentine Will Face ESG And Execution Risks
Key Takeaways Long-term demand and revenue growth are threatened by global shifts to renewables, increased gold recycling, and evolving alternative asset technologies, impacting gold pricing power. Heightened ESG regulation, ongoing operational challenges, and jurisdictional risks may drive up costs, shrink margins, and intensify earnings and revenue volatility.
View narrative
CA$9.53
FV
12.6% overvalued
intrinsic discount
24.82%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Baby Bunting Group
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Australian Store Oversaturation And Cost Pressures Will Curb Expansion
Key Takeaways Declining birth rates and increased supplier direct-to-consumer activity threaten long-term revenue growth and weaken market positioning for specialty retailers. Intensifying online competition, rising operational costs, and aggressive physical expansion may erode margins and reduce earnings quality over time.
View narrative
AU$1.80
FV
33.3% overvalued
intrinsic discount
10.08%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Value any company in seconds
Popular companies